AstraZeneca Expects To Get Data On The Effectiveness Of The COVID-19 Vaccine By The End Of The Year
British pharmaceutical company AstraZeneca expects to find out by the end of the year whether the vaccine it is developing protects against coronavirus, if the firm can resume interrupted trials of the drug, according to Reuters, citing the head of the company Pascal Soriot.
"We have until the end of the year to find out if a potential vaccine protects against COVID-19," he said.
According to Soriot, more tests are required to establish an accurate diagnosis in a test participant who has previously been found to have an "undesirable effect." The head of AstraZeneca stressed that the data on the diagnosis would be passed to the independent safety Commission, which is then expected to inform the company whether it can continue testing.
Earlier it became known that clinical trials of the AstraZeneca coronavirus vaccine were suspended due to a possible undesirable effect in one of the participants from the UK. The Financial Times newspaper, citing informed sources, reported that the tests could resume next week. According to the publication's interlocutors, the tests were suspended after the discovery of a rare inflammatory disease in the volunteer — transverse myelitis.
The AstraZeneca vaccine, which is being developed together with Oxford specialists, moved to the third phase of trials in the US in August. Earlier, AstraZeneca tests began in the UK, Brazil, and South Africa. The company is developing a vaccine based on monkey adenovirus vectors.